Perceptive Advisors LLC Sells 35,000 Shares of Repligen Corporation $RGEN

Perceptive Advisors LLC lessened its position in Repligen Corporation (NASDAQ:RGEN) by 11.1% in the first quarter, HoldingsChannel reports. The firm owned 280,541 shares of the biotechnology company’s stock after selling 35,000 shares during the quarter. Perceptive Advisors LLC’s holdings in Repligen were worth $33,053,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. AQR Capital Management LLC bought a new position in Repligen in the first quarter worth $262,000. Jones Financial Companies Lllp boosted its holdings in shares of Repligen by 3,850.6% during the 1st quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company’s stock valued at $814,000 after buying an additional 6,238 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Repligen by 16.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company’s stock valued at $18,067,000 after buying an additional 20,375 shares in the last quarter. Bank of Nova Scotia grew its position in shares of Repligen by 88.0% in the 2nd quarter. Bank of Nova Scotia now owns 31,747 shares of the biotechnology company’s stock worth $3,951,000 after buying an additional 14,860 shares during the period. Finally, Daiwa Securities Group Inc. grew its position in shares of Repligen by 29.7% in the 2nd quarter. Daiwa Securities Group Inc. now owns 31,194 shares of the biotechnology company’s stock worth $3,880,000 after buying an additional 7,148 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Royal Bank Of Canada initiated coverage on shares of Repligen in a research report on Thursday, May 14th. They set an “outperform” rating and a $160.00 price target for the company. Wolfe Research began coverage on shares of Repligen in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $145.00 price objective on the stock. Evercore reaffirmed an “outperform” rating and set a $160.00 target price on shares of Repligen in a research note on Monday, July 6th. Roth Capital assumed coverage on shares of Repligen in a report on Friday, April 17th. They set a “buy” rating and a $160.00 target price for the company. Finally, Weiss Ratings raised Repligen from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, July 14th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Repligen presently has a consensus rating of “Moderate Buy” and a consensus target price of $166.43.

Repligen Price Performance

Shares of NASDAQ:RGEN opened at $141.01 on Friday. The business has a fifty day moving average price of $134.66 and a 200-day moving average price of $131.60. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.05 and a quick ratio of 7.78. The company has a market capitalization of $7.96 billion, a PE ratio of 193.16, a PEG ratio of 2.62 and a beta of 1.06. Repligen Corporation has a 1-year low of $100.99 and a 1-year high of $175.77.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The company had revenue of $204.13 million for the quarter, compared to analysts’ expectations of $201.59 million. During the same quarter in the previous year, the business posted $0.26 EPS. Repligen’s revenue was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. As a group, equities analysts expect that Repligen Corporation will post 2.06 EPS for the current fiscal year.

Insider Transactions at Repligen

In other Repligen news, CFO Jason K. Garland sold 733 shares of Repligen stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the transaction, the chief financial officer directly owned 19,359 shares of the company’s stock, valued at approximately $2,807,055. The trade was a 3.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.60% of the company’s stock.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.